Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated patients’ treatment preferences and the imp...

Полное описание

Библиографические подробности

Главные авторы:	Teri J Mauch, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon, Katherine Garlo, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P Pham, Tara Symonds, Ioannis Tomazos, Yan Wang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Becaris Publishing Limited 2023-07-01
Серии:	Journal of Comparative Effectiveness Research
Предметы:	ahus atypical hemolytic uremic syndrome caregiver preference eculizumab patient-reported outcomes patient preference quality of life ravulizumab treatment preference
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!